CHCHD2 Protein

CHCHD2 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CHCHD2 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CHCHD2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>CHCHD2</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=CHCHD2" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">58 edges</a></td>
</tr>
</table>

Alternative Names: COXO7L2, P9IN, Mitochondrial Protein CHCHD2 Gene: CHCHD2 (Chromosome 7p13) Protein Family: Coiled-Coil-Helix-Coiled-Coil-Helix (CHCHD) domain proteins Molecular Weight: ~26 kDa

Introduction

CHCHD2 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CHCHD2 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CHCHD2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>CHCHD2</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=CHCHD2" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">58 edges</a></td>
</tr>
</table>

Alternative Names: COXO7L2, P9IN, Mitochondrial Protein CHCHD2 Gene: CHCHD2 (Chromosome 7p13) Protein Family: Coiled-Coil-Helix-Coiled-Coil-Helix (CHCHD) domain proteins Molecular Weight: ~26 kDa

Introduction

CHCHD2 (Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 2) is a small mitochondrial protein that plays critical roles in mitochondrial function, cellular metabolism, and Parkinson's disease (PD) pathogenesis. The protein was originally identified as a candidate nuclear-encoded mitochondrial protein and later discovered to be associated with familial Parkinson's disease through genetic studies. CHCHD2 is highly expressed in dopaminergic neurons of the substantia nigra pars compacta, explaining the selective vulnerability of these neurons in PD.

The identification of CHCHD2 as a PD susceptibility gene established an important link between mitochondrial dysfunction and neurodegeneration. The protein localizes to the mitochondrial intermembrane space and inner membrane, where it participates in oxidative phosphorylation, mitochondrial dynamics, and cellular response to oxidative stress. Understanding CHCHD2 function provides insights into the molecular mechanisms underlying dopaminergic neuron degeneration in PD.

Molecular Function and Biochemistry

Protein Structure

CHCHD2 belongs to the CHCH domain-containing protein family, characterized by the presence of one or more coiled-coil-helix-coiled-coil-helix (CHCH) domains. Each CHCH domain consists of approximately 50-60 amino acids containing two cysteine residues separated by 10-11 residues that form a disulfide bond, giving the domain a distinctive fold.

The CHCHD2 protein structure includes:

• N-terminal Domain: Variable region with potential mitochondrial targeting sequence
• CHCH Domain 1: First coiled-coil-helix-coiled-coil-helix domain mediating protein-protein interactions
• CHCH Domain 2: Second CHCH domain involved in dimerization and interactions with mitochondrial proteins
• C-terminal Region: Contains conserved cysteine residues for metal binding

Mitochondrial Localization

CHCHD2 localizes to the mitochondrial intermembrane space and inner membrane through an N-terminal targeting sequence. The protein utilizes a non-canonical mitochondrial import pathway that involves:

The mitochondrial localization is essential for CHCHD2 function, as mutations affecting mitochondrial targeting lead to loss of function.

Interaction Partners

CHCHD2 interacts with multiple mitochondrial proteins:

These interactions position CHCHD2 as a scaffold protein that coordinates mitochondrial respiratory chain assembly and function.

Role in Oxidative Phosphorylation

CHCHD2 plays a direct role in oxidative phosphorylation:

• Complex IV Assembly: CHCHD2 is required for proper assembly and stability of cytochrome c oxidase (Complex IV)
• Electron Transport: Facilitates electron transfer within the respiratory chain
• ATP Production: Loss of CHCHD2 reduces mitochondrial ATP production
• Oxygen Consumption: CHCHD2 deficiency decreases cellular oxygen consumption rate

Disease Associations

Parkinson's Disease

CHCHD2 is firmly established as a Parkinson's disease gene:

• Genetic Evidence: Multiple pathogenic mutations identified in familial PD patients, including missense mutations (R146H, T168I, A181T, P194L) and splicing mutations
• Pathogenic Variants: p.T61I and p.R146H are established pathogenic variants causing autosomal dominant PD
• Brain Expression: CHCHD2 is highly expressed in substantia nigra dopaminergic neurons, the neurons most vulnerable in PD
• Mitochondrial Dysfunction: PD-associated mutations impair Complex IV assembly and function

• Complex IV Deficiency: Reduced cytochrome c oxidase activity leads to mitochondrial dysfunction
• Oxidative Stress: Impaired respiratory chain increases reactive oxygen species production
• Energy Failure: Reduced ATP production compromises neuronal viability
• Apoptosis: Mitochondrial dysfunction triggers apoptotic pathways

Mitochondrial Myopathy

CHCHD2 mutations have been associated with mitochondrial myopathy:

• Clinical Presentation: Exercise intolerance, muscle weakness, ragged-red fibers
• Biochemical Defect: Complex IV deficiency in muscle tissue
• Histopathology: Accumulation of abnormal mitochondria in muscle fibers

Amyotrophic Lateral Sclerosis

CHCHD2 and its paralog CHCHD10 have been linked to ALS:

• Protein Aggregation: CHCHD2 is found in motor neuron inclusions in ALS
• Mitochondrial Dysfunction: CHCHD2 deficiency contributes to mitochondrial dysfunction in ALS models
• Interaction with ALS Proteins: CHCHD2 interacts with SOD1 and FUS, proteins mutated in familial ALS

Aging and Metabolic Disorders

Beyond PD, CHCHD2 is implicated in:

• Aging: CHCHD2 expression decreases with age, potentially contributing to age-related mitochondrial dysfunction
• Metabolic Syndrome: Altered CHCHD2 expression in obesity and diabetes models
• Cancer: Some studies suggest altered CHCHD2 expression in certain cancers

Clinical Significance

Genetic Testing

CHCHD2 is included in panels for familial Parkinson's disease genetic testing:

• Testing Indication: Early-onset PD, family history, atypical features
• Interpretation: Pathogenic variants confirm diagnosis; variants of uncertain significance require functional assessment
• Counseling Implications: Autosomal dominant inheritance with variable penetrance

Biomarker Potential

CHCHD2 as a biomarker is under investigation:

• CSF CHCHD2: Potential marker of mitochondrial dysfunction in PD
• Blood CHCHD2: Altered expression in peripheral blood mononuclear cells
• Imaging: PET ligands targeting mitochondrial function may reflect CHCHD2 activity

Therapeutic Targeting

Strategies targeting CHCHD2 are being explored:

• Gene Therapy: AAV-mediated CHCHD2 expression to restore mitochondrial function
• Small Molecules: Compounds that enhance CHCHD2 expression or function
• Mitochondrial Protectants: Agents that bypass Complex IV deficiency
• Antioxidants: Reducing oxidative stress to protect dopaminergic neurons

Genetics and Population Studies

Gene Variants

Multiple pathogenic variants in CHCHD2 have been identified:

• p.T61I: First identified variant in Japanese PD family, reduces Complex IV activity
• p.R146H: Pathogenic variant causing typical PD phenotype
• p.T168I: Associated with early-onset PD
• p.A181T: Found in PD patients with rapid progression
• p.P194L: Associated with atypical features

• rs5030655: Intronic variant potentially affecting splicing
• rs41305253: Promoter variant associated with altered expression

Epidemiology

CHCHD2-related PD accounts for a small but significant proportion of familial PD:

• Frequency: ~0.5-1% of familial PD cases
• Ethnic Distribution: Initially identified in Japanese families, subsequently found in other populations
• Penetrance: Variable, with some carriers remaining asymptomatic into late life

Animal Models

CHCHD2 knockdown and knockout models demonstrate:

• Drosophila: CHCHD2 knockdown leads to mitochondrial dysfunction and reduced lifespan
• Mouse: Conditional knockout shows Complex IV deficiency and age-dependent neurodegeneration
• Cell Lines: siRNA knockdown reduces Complex IV activity and increases ROS

Research Directions

Current Research Focus

Gaps in Knowledge

• How CHCHD2 mutations specifically affect dopaminergic neurons
• The complete interactome of CHCHD2 in neurons
• Why Complex IV is particularly affected by CHCHD2 dysfunction
• Potential for CHCHD2-targeted therapies to modify disease progression

Molecular Mechanisms of Neurodegeneration

Complex IV Assembly and Function

CHCHD2 plays a crucial role in cytochrome c oxidase (Complex IV) assembly:

• Early Assembly Factors: CHCHD2 participates in early Complex IV assembly as a scaffold
• Stability: CHCHD2 stabilizes assembled Complex IV in the inner membrane
• Dimerization: CHCHD2 promotes Complex IV dimerization essential for function

• Reduced Complex IV holoenzyme formation
• Increased degradation of unassembled subunits
• Electron transport chain dysfunction
• Increased ROS production

Mitochondrial Dynamics

CHCHD2 influences mitochondrial dynamics:

• Fusion: CHCHD2 deficiency impairs mitochondrial fusion through altered OPA1 processing
• Fission: Abnormal fission leads to fragmented mitochondria
• Quality Control: Impaired mitophagy due to reduced PINK1/Parkin signaling
• Transport: Altered mitochondrial trafficking in neurons

Energy Metabolism

The impact on cellular energetics includes:

• ATP Production: Reduced Complex IV activity decreases ATP synthesis
• Oxygen Consumption: Impaired coupling reduces cellular respiration
• Glycolysis Compensation: Cells shift to glycolysis, increasing lactate
• NADH/NAD+ Ratio: Altered redox state affects sirtuin activity

Oxidative Stress

CHCHD2 dysfunction leads to oxidative stress:

• ROS Generation: Electron leak from impaired Complex IV increases superoxide
• Antioxidant Depletion: GSH and other antioxidants become exhausted
• DNA Damage: Oxidative damage to nuclear and mitochondrial DNA
• Lipid Peroxidation: Membrane damage from ROS

Clinical Translation

Diagnostic Applications

CHCHD2 testing has clinical utility:

• Genetic Testing: Available for familial PD cases
• Counselling: Important for family planning and risk assessment
• Differential Diagnosis: Helps distinguish PD from other movement disorders

Biomarker Development

Potential biomarkers include:

• Blood CHCHD2: mRNA levels correlate with disease severity
• CSF CHCHD2: Protein levels indicate mitochondrial dysfunction
• Imaging: Mitochondrial function imaging may reflect CHCHD2 status

Therapeutic Approaches in Development

Gene Therapy

• AAV-CHCHD2: Restores CHCHD2 expression in neurons
• Gene Editing: Corrects pathogenic variants using CRISPR
• Regulatory Elements: Upregulation through promoter activation

Small Molecules

• Complex IV Bypass: Agents that improve electron transfer
• Antioxidants: Mitochondria-targeted antioxidants (MitoQ, MitoE)
• Expression Enhancers: Compounds that increase CHCHD2 transcription

Mitochondrial Protectants

• CoQ10: Electron carrier that bypasses Complex IV
• Idebenone: Synthetic analog of CoQ10
• ATP Restoration: Agents that restore cellular energy

Animal Model Studies

Drosophila melanogaster

• Knockdown Phenotype: Reduced lifespan, mitochondrial dysfunction
• Rescue Studies: Human CHCHD2 expression restores function
• Interaction Studies: Genetic modifiers identify pathway components

Mus musculus

• Conditional Knockout: Neuron-specific deletion causes neurodegeneration
• Age-Dependent Phenotype: Progressive mitochondrial dysfunction
• Behavioral Studies: Motor deficits similar to PD

Cellular Models

• iPSC-Derived Neurons: Patient neurons show Complex IV deficiency
• CRISPR Models: Isogenic lines with corrected variants
• Drug Screening: Platforms for therapeutic compound identification

Conclusions

CHCHD2 represents a critical link between mitochondrial dysfunction and Parkinson's disease pathogenesis. Its role in Complex IV assembly and mitochondrial dynamics explains the selective vulnerability of dopaminergic neurons. While the genetic evidence firmly establishes CHCHD2 as a PD gene, significant challenges remain in developing effective therapies. The relatively low frequency of CHCHD2-related PD underscores the importance of understanding its molecular mechanisms, which may provide insights applicable to sporadic disease.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Pathway Diagram

The following diagram shows the key molecular relationships involving CHCHD2 Protein discovered through SciDEX knowledge graph analysis: